An automated, closed system for rapid manufacturing of engineered T cells

Cell & Gene Therapy Insights 2023; 9(8), –1199

DOI: 10.18609/cgti.2023.157

Published: 15 January
Innovator Insight
Ian Johnston

The recent successes of CAR T cell therapy in fighting hematologic malignancies have led to tremendous interest in the immunotherapeutic field, whilst the great potential of genetically modified T cells now expands into solid tumors and infectious diseases. However, the manufacturing processes used for engineering T cells consist of various complex procedures, are labor intensive, and represent some of the biggest challenges in this area. This article will describe the CliniMACS Prodigy® Platform and the new associated T Cell Transduction—Large Scale (TCT–LS) process, and present data from CD8+ TCR-modified T-cell engineering in the setting of acute myeloid leukemia. Process details and differentiators will be shared, along with limitations and how to choose the right process type for your requirements.